MG-1122-A

N/A

Report date: 2026/03/19 16:57:23

Base Information

Drug NameMG-1122-A

Drug Alias NameAnti-Mesothelin/Anti-CD3 Bispecific T-Cell Engager (Mogam Biotechnology Institute)MG-1122-A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionT cell surface glycoprotein CD3 modulatorsMesothelin modulators

TargetsMesothelinT cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMogam Biotechnology Institute

China Registration ClassN/A

Develop Information

Active CompaniesMogam Biotechnology Institute

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A